Amneal Pharmaceuticals, Inc. Class A Common Stock
AMRX Real Time Price USDRecent trades of AMRX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AMRX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$60,000 Jul 16, 2025 Issue: Health Issues
-
$910,000 Apr 21, 2025 Issue: Health Issues
-
$210,000 Jan 21, 2025 Issue: Health Issues
-
$230,000 Jan 21, 2025 Issue: Health Issues
-
$240,000 Jan 21, 2025 Issue: Health Issues
-
$850,000 Jan 21, 2025 Issue: Health Issues
-
$40,000 Apr 20, 2022 Issue: Pharmacy
-
$60,000 Jan 20, 2022 Issue: Pharmacy
-
$60,000 Oct 20, 2021 Issue: Pharmacy
-
$60,000 Jul 20, 2021 Issue: Pharmacy
-
$60,000 Apr 20, 2021 Issue: Pharmacy
-
$60,000 Jan 21, 2021 Issue: Pharmacy
-
$60,000 Oct 20, 2020 Issue: Pharmacy
-
$50,000 Jul 20, 2020 Issue: Pharmacy
-
$20,000 Feb 01, 2019 Issue: None
-
$20,000 Jan 18, 2019 Issue: None
-
$20,000 Oct 08, 2018 Issue: None
-
$20,000 Jul 12, 2018 Issue: None
-
$40,000 Apr 16, 2018 Issue: Health Issues Budget/Appropriations
-
$40,000 Jan 20, 2018 Issue: Trade (domestic/foreign) Health Issues
-
$40,000 Dec 28, 2017 Issue: Health Issues
-
$40,000 Oct 19, 2017 Issue: Health Issues
-
$40,000 Jul 19, 2017 Issue: Health Issues
-
$40,000 Apr 20, 2017 Issue: Health Issues
-
$40,000 Oct 20, 2016 Issue: Pharmacy Health Issues
-
$40,000 Jul 19, 2016 Issue: Health Issues Pharmacy
-
$40,000 Apr 14, 2016 Issue: Pharmacy Health Issues
-
$40,000 Jan 15, 2016 Issue: Pharmacy Budget/Appropriations Copyright/Patent/Trademark Health Issues
-
$40,000 Oct 19, 2015 Issue: Pharmacy Health Issues Copyright/Patent/Trademark
-
$40,000 Jul 14, 2015 Issue: Pharmacy Health Issues Budget/Appropriations
-
$10,000 Apr 17, 2015 Issue: Health Issues Medicare/Medicaid Budget/Appropriations Pharmacy
-
$40,000 Apr 17, 2015 Issue: Health Issues Budget/Appropriations Pharmacy
-
$30,000 Jan 20, 2015 Issue: Pharmacy
-
$20,000 Jan 18, 2015 Issue: Insurance Health Issues Taxation/Internal Revenue Code Medicare/Medicaid Budget/Appropriations Pharmacy
-
$10,000 Oct 18, 2014 Issue: Pharmacy Taxation/Internal Revenue Code Health Issues Budget/Appropriations Insurance Food Industry (safety, labeling, etc.) Medicare/Medicaid
-
$30,000 Oct 15, 2014 Issue: Pharmacy
-
$30,000 Jul 18, 2014 Issue: Pharmacy Health Issues Budget/Appropriations
-
$30,000 Apr 16, 2014 Issue: Pharmacy Health Issues Budget/Appropriations
-
$25,000 Jan 16, 2014 Issue: Budget/Appropriations Health Issues Pharmacy
Estimated quarterly lobbying spending
AMRX Revenue by Segment or Geography
New patents grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to AMRX
Recent picks made for AMRX stock on CNBC
ETFs with the largest estimated holdings in AMRX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $AMRX stock a Buy, Sell, or Hold?
- What is the price target for $AMRX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $AMRX stock?
- Who owns the most shares of $AMRX stock?
- What funds own $AMRX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AMRX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.